Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 342
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NB7EE021D24EN
Leaflet:

Download PDF Leaflet

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016’, provides an overview of the Non-Alcoholic Steatohepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
  • The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects
  • The report assesses Non-Alcoholic Steatohepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Non-Alcoholic Steatohepatitis Overview
Therapeutics Development
Pipeline Products for Non-Alcoholic Steatohepatitis - Overview
Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis
Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies
Non-Alcoholic Steatohepatitis - Therapeutics under Investigation by Universities/Institutes
Non-Alcoholic Steatohepatitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Non-Alcoholic Steatohepatitis - Products under Development by Companies
Non-Alcoholic Steatohepatitis - Products under Investigation by Universities/Institutes
Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development
Akarna Therapeutics Ltd.
AlbireoPharma
Alnylam Pharmaceuticals, Inc.
Amunix Operating Inc.
Aquinox Pharmaceuticals Inc.
Arisaph Pharmaceuticals, Inc.
AstraZeneca Plc
BiOrion Technologies B.V.
Bird Rock Bio, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
Cardax Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
Conatus Pharmaceuticals Inc.
Connexios Life Sciences Pvt. Ltd.
Daiichi Sankyo Company, Limited
DURECT Corporation
Dynavax Technologies Corporation
Eli Lilly and Company
Enanta Pharmaceuticals, Inc.
Exicure, Inc.
Galectin Therapeutics, Inc.
Galmed Pharmaceuticals Ltd.
Genextra S.p.a.
Genfit SA
GenKyoTex S.A.
Gilead Sciences, Inc.
GRI Bio, Inc.
iCo Therapeutics Inc.
Immuron Limited
Inventiva
Ionis Pharmaceuticals, Inc.
Ixchel Pharma, LLC
Jenrin Discovery, Inc.
Kissei Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Matinas BioPharma Holdings, Inc.
Merck & Co., Inc.
Mitochon Pharmaceuticals, Inc.
Naia Limited
NGM Biopharmaceuticals, Inc.
Nimbus Therapeutics, LLC
Nippon Chemiphar Co., Ltd.
Nitto Denko Corporation
Novartis AG
NovaTarg Therapeutics, Inc
Nuevolution AB
Pharmaxis Limited
Promethera Biosciences S.A.
ProMetic Life Sciences Inc.
Protalix BioTherapeutics, Inc.
Saje Pharma, LLC
Shire Plc
Stelic Institute & Co., Inc.
Sucampo Pharmaceuticals, Inc.
TaiwanJ Pharmaceuticals Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Therapix Biosciences Ltd
Tobira Therapeutics, Inc.
Vascular Biogenics Ltd.
Verlyx Pharma Inc.
Viking Therapeutics, Inc.
Virobay Inc.
Zafgen Inc.
Zydus Cadila Healthcare Limited
Non-Alcoholic Steatohepatitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile
(leucine + PDE5 Inhibitor) - Drug Profile
A-4250 - Drug Profile
AC-261066 - Drug Profile
AM-0010 - Drug Profile
AMX-342 - Drug Profile
Antisense Oligonucleotides for Non-Alcoholic Steatohepatitis - Drug Profile
AQX-1125 - Drug Profile
Aramchol - Drug Profile
ARI-3037MO - Drug Profile
AZD-4076 - Drug Profile
bertilimumab - Drug Profile
BMS-986036 - Drug Profile
BMS-986171 - Drug Profile
BOT-191 - Drug Profile
CAT-2000 Series - Drug Profile
CAT-2054 - Drug Profile
CDX-085 - Drug Profile
cenicriviroc mesylate - Drug Profile
CER-209 - Drug Profile
CF-102 - Drug Profile
CNX-014 - Drug Profile
CNX-023 - Drug Profile
CNX-024 - Drug Profile
CNX-025 - Drug Profile
DRX-065 - Drug Profile
DUR-928 - Drug Profile
DV-1179 - Drug Profile
EDP-305 - Drug Profile
elafibranor - Drug Profile
emricasan - Drug Profile
etanercept biosimilar - Drug Profile
evogliptin - Drug Profile
GKT-831 - Drug Profile
GRI-0621 - Drug Profile
GRMD-02 - Drug Profile
GS-9674 - Drug Profile
HepaStem - Drug Profile
IMM-124E - Drug Profile
IONIS-DGAT2Rx - Drug Profile
IVA-337 - Drug Profile
IXC-303 - Drug Profile
IXC-305 - Drug Profile
JD-5037 - Drug Profile
JKB-119 - Drug Profile
JKB-121 - Drug Profile
linagliptin - Drug Profile
LJN-452 - Drug Profile
MAT-8800 - Drug Profile
MGL-3196 - Drug Profile
MGL-3745 - Drug Profile
MP-301 - Drug Profile
MSDC-0602 - Drug Profile
MT-2002 - Drug Profile
NC-101 - Drug Profile
NC-2400 - Drug Profile
ND-630 - Drug Profile
ND-654 - Drug Profile
ND-L02s0201 - Drug Profile
NDI-010976 - Drug Profile
NGM-282 - Drug Profile
NGM-313 - Drug Profile
NGM-386 - Drug Profile
NGM-395 - Drug Profile
NP-201 Program - Drug Profile
obeticholic acid - Drug Profile
PBI-4050 - Drug Profile
pentamidine isethionate - Drug Profile
PXS-4728A - Drug Profile
PXS-5033A - Drug Profile
PZ-235 - Drug Profile
remogliflozin etabonate - Drug Profile
RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders - Drug Profile
RTU-1096 - Drug Profile
RYI-018 - Drug Profile
saroglitazar - Drug Profile
selonsertib - Drug Profile
selonsertib + simtuzumab - Drug Profile
simtuzumab - Drug Profile
Small Molecule for Non-Alcoholic Steatohepatitis - Drug Profile
Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile
Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile
Small Molecule to Inhibit DGAT-2 for Dyslipidemia and Non-Alcoholic Steatohepatitis - Drug Profile
Small Molecule to Inhibit SCD-1 for Non-alcoholic Steatohepatitis - Drug Profile
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile
Small Molecules to Antagonize Integrin for Non-Alcoholic Steatohepatitis - Drug Profile
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile
Small Molecules to Inhibit MLK3 for Non-Alcoholic Steatohepatitis - Drug Profile
Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile
solithromycin - Drug Profile
SPL-891.1 - Drug Profile
SR-9238 - Drug Profile
STNM-09 - Drug Profile
TEV-45478 - Drug Profile
TGFTX-3 - Drug Profile
tipelukast - Drug Profile
TRX-318 - Drug Profile
VB-201 - Drug Profile
VB-703 - Drug Profile
VBY-376 - Drug Profile
VK-2809 - Drug Profile
volixibat potassium - Drug Profile
ZGN-839 - Drug Profile
Non-Alcoholic Steatohepatitis - Dormant Projects
Non-Alcoholic Steatohepatitis - Discontinued Products
Non-Alcoholic Steatohepatitis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2016
Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Akarna Therapeutics Ltd., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by AlbireoPharma, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Amunix Operating Inc. , H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by AstraZeneca Plc, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by BiOrion Technologies B.V., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Bird Rock Bio, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Bristol-Myers Squibb Company, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Can-Fite BioPharma Ltd., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Cerenis Therapeutics Holding SA, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by DURECT Corporation, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Dynavax Technologies Corporation, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Eli Lilly and Company, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Exicure, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Galectin Therapeutics, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Galmed Pharmaceuticals Ltd., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Genextra S.p.a., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Genfit SA, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by GenKyoTex S.A., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Gilead Sciences, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by GRI Bio, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by iCo Therapeutics Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Immuron Limited, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Inventiva, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Ixchel Pharma, LLC, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Jenrin Discovery, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Merck & Co., Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Naia Limited, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Nimbus Therapeutics, LLC, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Nitto Denko Corporation, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Novartis AG, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by NovaTarg Therapeutics, Inc, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Nuevolution AB, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Pharmaxis Limited, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Promethera Biosciences S.A., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by ProMetic Life Sciences Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Saje Pharma, LLC, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Shire Plc, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Stelic Institute & Co., Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Therapix Biosciences Ltd, H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Tobira Therapeutics, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Vascular Biogenics Ltd., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Verlyx Pharma Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Viking Therapeutics, Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Virobay Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Zafgen Inc., H2 2016
Non-Alcoholic Steatohepatitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Non-Alcoholic Steatohepatitis - Dormant Projects, H2 2016
Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..1), H2 2016
Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..2), H2 2016
Non-Alcoholic Steatohepatitis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2016
Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

Akarna Therapeutics Ltd.
AlbireoPharma
Alnylam Pharmaceuticals, Inc.
Amunix Operating Inc.
Aquinox Pharmaceuticals Inc.
Arisaph Pharmaceuticals, Inc.
AstraZeneca Plc
BiOrion Technologies B.V.
Bird Rock Bio, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
Cardax Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
Conatus Pharmaceuticals Inc.
Connexios Life Sciences Pvt. Ltd.
Daiichi Sankyo Company, Limited
DURECT Corporation
Dynavax Technologies Corporation
Eli Lilly and Company
Enanta Pharmaceuticals, Inc.
Exicure, Inc.
Galectin Therapeutics, Inc.
Galmed Pharmaceuticals Ltd.
Genextra S.p.a.
Genfit SA
GenKyoTex S.A.
Gilead Sciences, Inc.
GRI Bio, Inc.
iCo Therapeutics Inc.
Immuron Limited
Inventiva
Ionis Pharmaceuticals, Inc.
Ixchel Pharma, LLC
Jenrin Discovery, Inc.
Kissei Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Matinas BioPharma Holdings, Inc.
Merck & Co., Inc.
Mitochon Pharmaceuticals, Inc.
Naia Limited
NGM Biopharmaceuticals, Inc.
Nimbus Therapeutics, LLC
Nippon Chemiphar Co., Ltd.
Nitto Denko Corporation
Novartis AG
NovaTarg Therapeutics, Inc
Nuevolution AB
Pharmaxis Limited
Promethera Biosciences S.A.
ProMetic Life Sciences Inc.
Protalix BioTherapeutics, Inc.
Saje Pharma, LLC
Shire Plc
Stelic Institute & Co., Inc.
Sucampo Pharmaceuticals, Inc.
TaiwanJ Pharmaceuticals Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Therapix Biosciences Ltd
Tobira Therapeutics, Inc.
Vascular Biogenics Ltd.
Verlyx Pharma Inc.
Viking Therapeutics, Inc.
Virobay Inc.
Zafgen Inc.
Zydus Cadila Healthcare Limited
Skip to top


Alcohol Addiction - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 138 pages

Ask Your Question

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: